NASDAQ:BMRN   BioMarin Pharmaceutical Inc.
Price thru resistance, FDA priority review, 50 day in range.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.